Long-term safety of posterior chamber implantable phakic contact lens for the correction of myopia

Abstract

PurposeTo review the safety of the implantable phakic contact lens (IPCL V1, Caregroup Sight Solutions, India) for correction of myopia and myopic astigmatism.MethodsRetrospective interventional case series including 134 eyes which underwent IPCL implantation for correction of myopia and myopic astigmatism at a tertiary eye care hospital in South India. Intraoperative and postoperative complications were analyzed. The following parameters were analyzed at preoperative and 1, 6 and 12 month postoperative visits: visual acuity (in logMAR) and manifest refraction, slit lamp bio microscopy, dilated fundus examination, IOP and endothelial cell density measurement.ResultsNo intraoperative complications were noted. Cataract was the most common postoperative complication, wherein three eyes (2.2%) underwent observation for visually insignificant anterior subcapsular cataract and one eye (0.7%) required surgical intervention. Four eyes developed transient increased IOP due to steroid response (3 eyes) and pupillary block glaucoma (1 eye). The endothelial cell loss noted over a 1-year follow-up was 2.01%±4.12% (P=0.71). One eye developed hypopyon on the third postoperative day, which resolved subsequently with an unaided vision of 20/20. No vision threatening complications were noted. The mean follow-up in the cohort was 25.66±16.45 months.ConclusionThe IPCL is a safe and effective treatment modality for correction of myopia and myopic astigmatism.

Presbyopia Management with Diffractive Phakic Posterior Chamber IOL.

“…And a similar result was obtained in a previous study, but only with a 6 month follow-up for the IPCL V 2.0 model [24]. However, with the previous IPCL platform (V 1.0) evaluated by other authors, using a surgical technique with the aid of viscoelastic substances, similar safe values were obtained [22,23].…”

“…Only 1.9% of eyes got 20/32 10 UDVA. Good refractive outcome was similar to what was previously reported for IPCL [22][23][24], which gives information about the efficiency of this lens to correct ametropias. Moreover, the obtained defocus curve gives information about how patients were capable of seeing at different distances without the aid of spectacles.…”

“…Posterior chamber pIOLs have improved considerably, however, to date, there are no extensive studies of the IPCL model. In two studies [22,23], authors have evaluated the previous IPCL model V1.0 (which needed a previous iridotomy). And with few differences, both works have reported best refractive outcomes without complications for correction of myopia and myopic astigmatism.…”

“…But pIOL implantation in the anterior chamber was associated with complications, which are widely described [19][20][21]. The posterior chamber implantable phakic contact lens called IPCL (Care Group, India) has proved its safety and efficacy for correction of myopia and myopic astigmatism [22][23][24] and the new model, "Diffractive IPCL V 2.0", arises as an option for presbyopia management. Based on these observations, the purpose of this work is to evaluate the safety and refractive efficiency of Diffractive IPCL V 2.0 in patients with myopia and/or myopic astigmatism and presbyopia.…”

<p>A Novel Concept of Correcting Presbyopia: First Clinical Results with a Phakic Diffractive Intraocular Lens</p>

“…The authors concluded IPCL to be a safe and effective treatment modality. 20 We did not find any indication that safety will become a major problem after implantation of the presbyopic IPCL. In one case in our group of patients, an explantation and re-implantation during the primary surgical procedure was necessary because the IOL turned out to be implanted upside-down due to the shooting process.…”